Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis

Connect Biopharma Holdings Limited announced that it has completed full enrollment of the phase II clinical trial evaluating CBP-307 in adult patients with moderate-to-severe ulcerative colitis.